0001096906-23-002066.txt : 20231031 0001096906-23-002066.hdr.sgml : 20231031 20231031122350 ACCESSION NUMBER: 0001096906-23-002066 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20231031 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20231031 DATE AS OF CHANGE: 20231031 FILER: COMPANY DATA: COMPANY CONFORMED NAME: UTAH MEDICAL PRODUCTS INC CENTRAL INDEX KEY: 0000706698 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 870342734 STATE OF INCORPORATION: UT FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-12575 FILM NUMBER: 231363230 BUSINESS ADDRESS: STREET 1: 7043 S 300 WEST CITY: MIDVALE STATE: UT ZIP: 84047 BUSINESS PHONE: 8015661200 8-K 1 utmd-20231031.htm UTAH MEDICAL PRODUCTS, INC. - FORM 8-K SEC FILING UTAH MEDICAL PRODUCTS, INC. - Form 8-K SEC filing
0000706698 false 0000706698 2023-10-31 2023-10-31

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C.  20549

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (date of earliest event reported):  October 31, 2023

 

 

UTAH MEDICAL PRODUCTS, INC.

(Exact name of registrant as specified in its charter)

 

 

 

 

 

Utah

 

000-12575

 

87-0342734

(State or other jurisdiction of

 

(Commission File Number)

 

(IRS Employer

incorporation or organization)

 

 

 

Identification No.)

 

 

 

 

 

7043 South 300 West

 

 

Midvale, Utah

 

84047

(Address of principal executive offices)

 

(Zip code)

 

 

 

Registrant’s telephone number, including area code:  

 

Phone: (801) 566-1200

 

 

 

n/a

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

 

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

 

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

 

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (Section 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (Section 240.12b-2 of this chapter).

 

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

ITEM 8.01—OTHER EVENTS

 

On October 31, 2023, Utah Medical Products, Inc. announced that it is increasing its regular quarterly cash dividend.  A dividend of $.30 per share is payable on January 3, 2024 to shareholders of record at the close of business on December 15, 2023.  A copy of the press release is attached hereto as Exhibit 99.1

 

 

ITEM 9.01—FINANCIAL STATEMENTS AND EXHIBITS

 

The following is filed as an exhibit to this report:  

 

Exhibit

Number*

 

 

Title of Document

 

 

Location

Item 99.1

 

Utah Medical Products, Inc. Increases Regular Quarterly Dividend

 

This filing

_______________________________________

*All exhibits are numbered with the number preceding the decimal indicating the applicable SEC reference number in Item 601 and the number following the decimal indicating the sequence of the particular document.  

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

UTAH MEDICAL PRODUCTS, INC.

 

 

 

 

 

 

 

 

 

Dated: October 31, 2023

By:

/s/ Kevin L. Cornwell

 

 

Kevin L. Cornwell,
Chief Executive Officer

 EX-99.1 2 utah_ex99z1.htm UTAH MEDICAL PRODUCTS, INC. INCREASES REGULAR QUARTERLY DIVIDEND

EXHIBIT 99.1

 

Utah Medical Products, Inc. Increases Regular Quarterly Dividend

Contact:  Brian Koopman

October 31, 2023

(801) 566-1200

 

 

Salt Lake City, Utah - Utah Medical Products, Inc. (Nasdaq: UTMD) announces that its Board of Directors approved a quarterly cash dividend of thirty cents ($.30) per share of common stock payable on January 3, 2024 to shareholders of record at the close of business on December 15, 2023.  This is a 1.7% increase over the prior regular quarterly cash dividend.

 

Utah Medical Products, Inc., with particular interest in health care for women and their babies, develops, manufactures and markets a broad range of disposable and reusable specialty medical devices recognized by clinicians in over a hundred countries around the world as the standard for obtaining optimal long term outcomes for their patients.  For more information about Utah Medical Products, Inc., visit UTMD’s website at www.utahmed.com.

 EX-101.DEF 3 utmd-20231031_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 4 utmd-20231031_lab.xml XBRL TAXONOMY EXTENSION LABELS LINKBASE DOCUMENT Entity Address, Address Line One Public Float Small Business Number of common stock shares outstanding Tax Identification Number (TIN) Trading Exchange Registrant Name Pre-commencement Tender Offer City Area Code Entity Address, City or Town Ex Transition Period Pre-commencement Issuer Tender Offer Entity Incorporation, State or Country Code Current with reporting Details Registrant CIK Voluntary filer Entity Address, State or Province Fiscal Year End Shell Company Interactive Data Current Amendment Flag Written Communications Emerging Growth Company SEC Form Local Phone Number Entity Address, Postal Zip Code Well-known Seasoned Issuer Period End date Amendment Description Trading Symbol Soliciting Material Entity File Number Filer Category EX-101.PRE 5 utmd-20231031_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT EX-101.SCH 6 utmd-20231031.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 000010 - Document - Document and Entity Information link:presentationLink link:definitionLink link:calculationLink XML 7 R1.htm IDEA: XBRL DOCUMENT v3.23.3
Document and Entity Information
Oct. 31, 2023
Details  
Registrant CIK 0000706698
Registrant Name UTAH MEDICAL PRODUCTS, INC.
SEC Form 8-K
Period End date Oct. 31, 2023
Tax Identification Number (TIN) 87-0342734
Emerging Growth Company false
Entity Incorporation, State or Country Code UT
Entity File Number 000-12575
Entity Address, Address Line One 7043 South 300 West
Entity Address, City or Town Midvale
Entity Address, State or Province UT
Entity Address, Postal Zip Code 84047
City Area Code 801
Local Phone Number 566-1200
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Amendment Flag false
XML 8 utmd-20231031_htm.xml IDEA: XBRL DOCUMENT 0000706698 2023-10-31 2023-10-31 0000706698 false 8-K 2023-10-31 UTAH MEDICAL PRODUCTS, INC. UT 000-12575 87-0342734 7043 South 300 West Midvale UT 84047 801 566-1200 false false false false false EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.3 html 1 19 1 false 0 0 false 0 false false R1.htm 000010 - Document - Document and Entity Information Sheet http://utahmed.com/20231031/role/idr_DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports utmd-20231031.htm utmd-20231031.xsd utmd-20231031_def.xml utmd-20231031_lab.xml utmd-20231031_pre.xml http://xbrl.sec.gov/dei/2023 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "utmd-20231031.htm": { "nsprefix": "fil", "nsuri": "http://utahmed.com/20231031", "dts": { "inline": { "local": [ "utmd-20231031.htm" ] }, "schema": { "local": [ "utmd-20231031.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "definitionLink": { "local": [ "utmd-20231031_def.xml" ] }, "labelLink": { "local": [ "utmd-20231031_lab.xml" ] }, "presentationLink": { "local": [ "utmd-20231031_pre.xml" ] } }, "keyStandard": 19, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 34, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 19 }, "report": { "R1": { "role": "http://utahmed.com/20231031/role/idr_DocumentDocumentAndEntityInformation", "longName": "000010 - Document - Document and Entity Information", "shortName": "Document and Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "D231031", "name": "dei:EntityRegistrantName", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "b", "span", "p", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "utmd-20231031.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "D231031", "name": "dei:EntityRegistrantName", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "b", "span", "p", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "utmd-20231031.htm", "first": true, "unique": true } } }, "tag": { "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://utahmed.com/20231031/role/idr_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r7" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://utahmed.com/20231031/role/idr_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Number of common stock shares outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://utahmed.com/20231031/role/idr_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r0" ] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://utahmed.com/20231031/role/idr_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Current with reporting", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://utahmed.com/20231031/role/idr_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r0" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://utahmed.com/20231031/role/idr_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r4" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://utahmed.com/20231031/role/idr_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://utahmed.com/20231031/role/idr_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r5" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://utahmed.com/20231031/role/idr_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://utahmed.com/20231031/role/idr_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Fiscal Year End", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://utahmed.com/20231031/role/idr_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://utahmed.com/20231031/role/idr_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "SEC Form", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://utahmed.com/20231031/role/idr_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://utahmed.com/20231031/role/idr_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r0" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://utahmed.com/20231031/role/idr_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Registrant CIK", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r0" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://utahmed.com/20231031/role/idr_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "us-gaap_TextBlockAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TextBlockAbstract", "lang": { "en-us": { "role": { "label": "Details" } } }, "auth_ref": [] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://utahmed.com/20231031/role/idr_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://utahmed.com/20231031/role/idr_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://utahmed.com/20231031/role/idr_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r0" ] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://utahmed.com/20231031/role/idr_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r2" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://utahmed.com/20231031/role/idr_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://utahmed.com/20231031/role/idr_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Trading Exchange", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r1" ] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://utahmed.com/20231031/role/idr_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://utahmed.com/20231031/role/idr_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r0" ] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://utahmed.com/20231031/role/idr_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r6" ] }, "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentDescription", "presentation": [ "http://utahmed.com/20231031/role/idr_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://utahmed.com/20231031/role/idr_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityVoluntaryFilers", "presentation": [ "http://utahmed.com/20231031/role/idr_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Voluntary filer", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://utahmed.com/20231031/role/idr_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Period End date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://utahmed.com/20231031/role/idr_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Ex Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r8" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://utahmed.com/20231031/role/idr_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://utahmed.com/20231031/role/idr_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Tax Identification Number (TIN)", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r0" ] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://utahmed.com/20231031/role/idr_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r8": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 15 0001096906-23-002066-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001096906-23-002066-xbrl.zip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end